Evaluating Gabapentin Effects on Brain Chemistry in Adults with Bipolar Disorder and Cannabis Use Using MRI

What this Trial Is About

Researchers are evaluating the effects of the FDA-approved medication Gabapentin in adults with Bipolar Disorder who also use marijuana. This study focuses on individuals aged 18 to 65 who have moderate or severe cannabis use disorder and bipolar I or II disorder, or schizoaffective disorder, bipolar type. The trial aims to understand how Gabapentin affects brain chemicals related to GABA and glutamate balance using MRI scans. Participants will be randomly assigned to receive either Gabapentin or a placebo. The study medication is taken 2 to 3 times daily for 17 days. There are five study visits during this period, including two MRI brain imaging scans, one before and one after treatment. Various clinical interviews and questionnaires will also be completed during these visits, alongside monitoring for possible side effects. During the study, participants undergo clinical assessments and provide information through questionnaires. The primary outcome measured is the change in prefrontal GABA concentrations from the start to the end of treatment using Proton Magnetic Resonance Spectroscopy. Safety and adherence to medication will be monitored throughout. The total participation time spans approximately 17 days, with all visits and assessments scheduled within this timeframe.

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders